Mechanism of inhibition of platelet aggregation by rutaecarpine, an alkaloid isolated from Evodia rutaecarpa

Joen Rong Sheu, Wei Chun Hung, Yen M. Lee, Mao Hsiung Yen

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

In this study, rutaecarpine was tested for its antiplatelet activities in human platelet-rich plasma. In human platelet-rich plasma, rutaecarpine (40-200 μM) inhibited aggregation stimulated by a variety of agonists (i.e., collagen, ADP, adrenaline and arachidonic acid). The antiplatelet activity of rutaecarpine (120 μM) was not significantly attenuated by pretreatment with the nitric oxide synthase inhibitor N(G)-mono-methyl-L-arginine (L-NMMA) (100 μM) or N(G)-nitro-L-arginine methyl ester (L-NAME) (200 μM) and with the guanylyl cyclase inhibitor methylene blue (100 μM). In addition, rutaecarpine (40-200 μM) did not significantly affect cyclic AMP and cyclic GMP levels in human washed platelets, whereas it significantly inhibited thromboxane B2 formation stimulated by collagen (10 μg/ml) and thrombin (0.1 U/ml). Furthermore, rutaecarpine (40-200 μM) inhibited [3H]inositol monophosphate formation stimulated by collagen and thrombin in [3H]myoinositol-loaded platelets. It is concluded that the antiplatelet effects of rutaecarpine are due to inhibition of thromboxane formation and phosphoinositide breakdown.

Original languageEnglish
Pages (from-to)469-475
Number of pages7
JournalEuropean Journal of Pharmacology
Volume318
Issue number2-3
DOIs
Publication statusPublished - Dec 30 1996

Fingerprint

Evodia
Platelet Aggregation
Alkaloids
Platelet-Rich Plasma
Collagen
NG-Nitroarginine Methyl Ester
Inositol
Thrombin
Blood Platelets
omega-N-Methylarginine
Thromboxane B2
Guanylate Cyclase
Methylene Blue
Thromboxanes
Cyclic GMP
Phosphatidylinositols
Arachidonic Acid
Human Activities
Nitric Oxide Synthase
Cyclic AMP

Keywords

  • Alkaloid
  • cAMP
  • cGMP
  • Phosphoinositide
  • Platelet, human
  • Rutaecarpine
  • Thromboxane A

ASJC Scopus subject areas

  • Cellular and Molecular Neuroscience
  • Pharmacology

Cite this

Mechanism of inhibition of platelet aggregation by rutaecarpine, an alkaloid isolated from Evodia rutaecarpa. / Sheu, Joen Rong; Hung, Wei Chun; Lee, Yen M.; Yen, Mao Hsiung.

In: European Journal of Pharmacology, Vol. 318, No. 2-3, 30.12.1996, p. 469-475.

Research output: Contribution to journalArticle

@article{f7791d2d4ecd4bde86038a02911af178,
title = "Mechanism of inhibition of platelet aggregation by rutaecarpine, an alkaloid isolated from Evodia rutaecarpa",
abstract = "In this study, rutaecarpine was tested for its antiplatelet activities in human platelet-rich plasma. In human platelet-rich plasma, rutaecarpine (40-200 μM) inhibited aggregation stimulated by a variety of agonists (i.e., collagen, ADP, adrenaline and arachidonic acid). The antiplatelet activity of rutaecarpine (120 μM) was not significantly attenuated by pretreatment with the nitric oxide synthase inhibitor N(G)-mono-methyl-L-arginine (L-NMMA) (100 μM) or N(G)-nitro-L-arginine methyl ester (L-NAME) (200 μM) and with the guanylyl cyclase inhibitor methylene blue (100 μM). In addition, rutaecarpine (40-200 μM) did not significantly affect cyclic AMP and cyclic GMP levels in human washed platelets, whereas it significantly inhibited thromboxane B2 formation stimulated by collagen (10 μg/ml) and thrombin (0.1 U/ml). Furthermore, rutaecarpine (40-200 μM) inhibited [3H]inositol monophosphate formation stimulated by collagen and thrombin in [3H]myoinositol-loaded platelets. It is concluded that the antiplatelet effects of rutaecarpine are due to inhibition of thromboxane formation and phosphoinositide breakdown.",
keywords = "Alkaloid, cAMP, cGMP, Phosphoinositide, Platelet, human, Rutaecarpine, Thromboxane A",
author = "Sheu, {Joen Rong} and Hung, {Wei Chun} and Lee, {Yen M.} and Yen, {Mao Hsiung}",
year = "1996",
month = "12",
day = "30",
doi = "10.1016/S0014-2999(96)00789-3",
language = "English",
volume = "318",
pages = "469--475",
journal = "European Journal of Pharmacology",
issn = "0014-2999",
publisher = "Elsevier",
number = "2-3",

}

TY - JOUR

T1 - Mechanism of inhibition of platelet aggregation by rutaecarpine, an alkaloid isolated from Evodia rutaecarpa

AU - Sheu, Joen Rong

AU - Hung, Wei Chun

AU - Lee, Yen M.

AU - Yen, Mao Hsiung

PY - 1996/12/30

Y1 - 1996/12/30

N2 - In this study, rutaecarpine was tested for its antiplatelet activities in human platelet-rich plasma. In human platelet-rich plasma, rutaecarpine (40-200 μM) inhibited aggregation stimulated by a variety of agonists (i.e., collagen, ADP, adrenaline and arachidonic acid). The antiplatelet activity of rutaecarpine (120 μM) was not significantly attenuated by pretreatment with the nitric oxide synthase inhibitor N(G)-mono-methyl-L-arginine (L-NMMA) (100 μM) or N(G)-nitro-L-arginine methyl ester (L-NAME) (200 μM) and with the guanylyl cyclase inhibitor methylene blue (100 μM). In addition, rutaecarpine (40-200 μM) did not significantly affect cyclic AMP and cyclic GMP levels in human washed platelets, whereas it significantly inhibited thromboxane B2 formation stimulated by collagen (10 μg/ml) and thrombin (0.1 U/ml). Furthermore, rutaecarpine (40-200 μM) inhibited [3H]inositol monophosphate formation stimulated by collagen and thrombin in [3H]myoinositol-loaded platelets. It is concluded that the antiplatelet effects of rutaecarpine are due to inhibition of thromboxane formation and phosphoinositide breakdown.

AB - In this study, rutaecarpine was tested for its antiplatelet activities in human platelet-rich plasma. In human platelet-rich plasma, rutaecarpine (40-200 μM) inhibited aggregation stimulated by a variety of agonists (i.e., collagen, ADP, adrenaline and arachidonic acid). The antiplatelet activity of rutaecarpine (120 μM) was not significantly attenuated by pretreatment with the nitric oxide synthase inhibitor N(G)-mono-methyl-L-arginine (L-NMMA) (100 μM) or N(G)-nitro-L-arginine methyl ester (L-NAME) (200 μM) and with the guanylyl cyclase inhibitor methylene blue (100 μM). In addition, rutaecarpine (40-200 μM) did not significantly affect cyclic AMP and cyclic GMP levels in human washed platelets, whereas it significantly inhibited thromboxane B2 formation stimulated by collagen (10 μg/ml) and thrombin (0.1 U/ml). Furthermore, rutaecarpine (40-200 μM) inhibited [3H]inositol monophosphate formation stimulated by collagen and thrombin in [3H]myoinositol-loaded platelets. It is concluded that the antiplatelet effects of rutaecarpine are due to inhibition of thromboxane formation and phosphoinositide breakdown.

KW - Alkaloid

KW - cAMP

KW - cGMP

KW - Phosphoinositide

KW - Platelet, human

KW - Rutaecarpine

KW - Thromboxane A

UR - http://www.scopus.com/inward/record.url?scp=0030607693&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030607693&partnerID=8YFLogxK

U2 - 10.1016/S0014-2999(96)00789-3

DO - 10.1016/S0014-2999(96)00789-3

M3 - Article

C2 - 9016940

AN - SCOPUS:0030607693

VL - 318

SP - 469

EP - 475

JO - European Journal of Pharmacology

JF - European Journal of Pharmacology

SN - 0014-2999

IS - 2-3

ER -